Company / Return on Equity (ROE)
Alaunos Therapeutics, Inc. Return on Equity (ROE) History
FY2012-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Return on Equity (ROE)
-226.8%
FY2025
5-year range
-557.2% / -64.5%
FY2021-FY2025
Trend
+59.3%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Alaunos Therapeutics, Inc. reports negative total equity of -226.8% in FY2025. Negative equity can occur when accumulated losses exceed contributed capital, as reported in the balance sheet from the SEC filing.
Based on SEC 10-K filings.
-226.8% in FY2025 with a 5-year CAGR of -170.9%.
Declined from -97.9% to -226.8% over the past 2 years.
Return on Equity (ROE) over time
Growth rates
- 3-Year Change
- -91.2pp
- 5-Year Change
- -170.9pp
- 10-Year Change
- -
Key checks
Key Insights
- In FY2025, return on equity (roe) increased 59.3% year-over-year.
- Peak return on equity (roe) was recorded in FY2013.
- Lowest return on equity (roe) in the period was in FY2024.
Company context
Key Data Points
- Altman Z-Score -3.79 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Return on Equity (ROE)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -226.8% | +59.3% |
| FY2024 | -557.2% | -469.3% |
| FY2023 | -97.9% | +27.9% |
| FY2022 | -135.6% | -110.3% |
| FY2021 | -64.5% | -15.4% |
| FY2020 | -55.9% | - |
| FY2019 | - | - |
| FY2018 | - | - |
| FY2013 | -7.9% | +75.2% |
| FY2012 | -32.0% | +0.0% |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026